Five novel and four recurrent point mutations in the antithrombin gene causing venous thrombosis

International Journal of Hematology

Volumn 78, Issue 1, 2003, Pages 79-83

  Nagaizumi, Keiko ^a   Inaba, Hiroshi ^a   Amano, Kagehiro ^a   Suzuki, Midori ^b   Arai, Morio ^a   Fukutake, Katsuyuki ^a  

^a TOKYO MEDICAL UNIVERSITY   (Japan)

^b DOKKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

Antithrombin; AT deficiency; Direct sequence; Point mutation; Venous thrombosis

Indexed keywords

ANTICOAGULANT AGENT; ANTITHROMBIN; PROTEINASE; SERINE PROTEINASE INHIBITOR; WARFARIN;

ADOLESCENT; ADULT; ALLELE; ANTITHROMBIN 2 DEFICIENCY; ANTITHROMBIN DEFICIENCY; ANTITHROMBIN GENE; ARTICLE; CARBOXY TERMINAL SEQUENCE; CLINICAL ARTICLE; DNA FLANKING REGION; ENZYME ACTIVE SITE; EXON; FEMALE; GENE AMPLIFICATION; GENE ISOLATION; GENE LOCATION; GENE SEQUENCE; GENETIC CONSERVATION; HETEROZYGOSITY; HUMAN; JAPAN; MALE; MISSENSE MUTATION; MUTATOR GENE; PLEIOTROPY; POINT MUTATION; POLYMERASE CHAIN REACTION; SPLICEOSOME; VEIN THROMBOSIS;

EID: 0041345760     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02983246     Document Type: Article

References (23)

1. Olds RJ, Lane DA, Chowdhury V, De Stefano V, Leone G, Thein SL. Complete nucleotide sequence of the antithrombin gene: evidence for homologous recombination causing thrombophilia. Biochemistry. 1993;32:4216-4224.
2. Olds RJ, Lane DA, Mille B, Chowdhury V, Thein SL. Antithrombin: the principal inhibitor of thrombin. Semin Thromb Hemost. 1994;20:353-372.
3. Sun XJ, Chang JY. Heparin binding domain of human antithrombin III inferred from the sequential reduction of its three disulfide linkages: an efficient method for structural analysis of partially reduced proteins. J Biol Chem. 1989;264:11288-11293.
4. Huber R, Carrell RW. Implications of the three-dimensional structure of alpha 1-antitrypsin for structure and function of serpins. Biochemistry. 1989;28:8951-8966.
5. Egeberg O. Inherited antithrombin deficiency causing thrombophilia. Thromb Diath Haemorrh. 1965;13:516-530.
6. Rosenberg RD. Actions and interactions of antithrombin and heparin. N Engl J Med. 1975;292:146-151.
7. Perry DJ, Carrell RW. Molecular genetics of human antithrombin deficiency. Hum Mutat. 1996;7:7-22.
8. Sas G. Classification of antithrombin III deficiencies: has a new tower of Babel been built? Thromb Haemost. 1988;60:530-531.
9. Lane DA, Kunz G, Olds RJ, Thein SL. Molecular genetics of antithrombin deficiency. Blood Rev. 1996;10:59-74.
10. Lane DA, Olds RJ, Conard J, et al. Pleiotropic effects of antithrombin strand 1C substitution mutations. J Clin Invest. 1992;90:2422-2433.
11. Nagaizumi K, Inaba H, Yoshida S, et al. Identification of a novel point mutation (Ala94 to Val) in a hereditary type I antithrombin III deficiency. Jpn J Thromb Haemost. 1996;7:472-480.
12. Lane DA, Bayston T, Olds RJ, et al. Antithrombin mutation database: 2nd (1997) update. Plasma Coagulation Inhibitors Subcommittee of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost. 1997;77:197-211.
13. Fitches AC, Appleby R, Lane DA, De Stefano V, Leone G, Olds RJ. Impaired cotranslational processing as a mechanism for type I antithrombin deficiency. Blood. 1998;92:4671-4676.
14. Perry DJ. Ectopic transcript analysis in human antithrombin deficiency. Blood Coagul Fibrinolysis. 1995;6:531-536.
15. Chowdhury V, Olds RJ, Lane DA, et al. Identification of nine novel mutations in type I antithrombin deficiency by heteroduplex screening. Br J Haematol. 1993;84:656-661.
16. Stein PE, Carrell RW. What do dysfunctional serpins tell us about molecular mobility and disease? Nat Struct Biol. 1995;2:96-113.
17. Bock SC, Marrinan JA, Radziejewska E. Antithrombin III Utah: proline-407 to leucine mutation in a highly conserved region near the inhibitor reactive site. Biochemistry. 1988;27:6171-6178.
18. Erdjument H, Lane DA, Ireland H, et al. Formation of a covalent disulfide-linked antithrombin-albumin complex by an antithrombin variant, antithrombin "Northwick Park." J Biol Chem. 1987; 262:13381-13384.
19. Erdjument H, Lane DA, Ireland H, et al. Antithrombin Milano, single amino acid substitution at the reactive site, Arg393 to Cys. Thromb Haemost. 1988;60:471-475.
20. Ireland H, Lane DA, Thompson E, Thein SL, Hach-Wunderle V, Scharrer I. Antithrombin Frankfurt I: arginine to cysteine substitution at the reactive site and formation of a variant antithrombin-albumin covalent complex. Thromb Haemost. 1991;65:913.
21. Borg JY, Brennan SO, Carrell RW, George P, Perry DJ, Shaw J. Antithrombin Rouen-IV 24 Arg-Cys: the amino-terminal contribution to heparin binding. FEBS Lett. 1990;266:163-166.
22. Koide T, Odani S, Takahashi K, Ono T, Sakuragawa N. Antithrombin III Toyama: replacement of arginine-47 by cysteine in hereditary abnormal antithrombin III that lacks heparin-binding ability. Proc Natl Acad Sci U S A. 1984;81:289-293.
23. Perry DJ, Daly ME, Colvin BT, Brown K, Carell RW. Two antithrombin mutations in a compound heterozygote: Met20Thr and Tyr166Cys. Am J Hematol. 1995;50:215-216.